Dentsply Sirona Reports Preliminary Q3 Net Sales Of Approximately $951M (Est $937.91M) And Adjusted EPS Of $0.49 - $0.51 (Est $0.47)
Dentsply Sirona Reports Preliminary Q3 Net Sales Of Approximately $951M (Est $937.91M) And Adjusted EPS Of $0.49 - $0.51 (Est $0.47)
Several factors contributed to reductions to forecasted revenues, lower operating margins, and expectations for lower future cash flows in the near term, resulting in an impairment during the third quarter for the aforementioned reporting units.For the third quarter 2024, the Company expects to report year-over-year net sales growth in Essential Dental Solutions, partially offset by declines in Orthodontic and Implant Solutions and Connected Technology Solutions segments.
到2024年第三季度，公司預計基礎牙科解決方案的淨銷售額將出現同比增長，部分抵消了正畸和種植解決方案以及連接技術解決方案區間的下降。
Wellspect Healthcare net sales are expected to be approximately flat due to timing with a large US distributor.
由於與一家大型美國經銷商的時機不同，預計Wellspect Healthcare的淨銷售額將基本持平。
The Company expects to record non-cash charges for the impairment of goodwill within the range of $450 - $550 million, net of tax, pertaining to two of its reporting units, Orthodontic Aligner Solutions and Implants & Prosthetic Solutions, which together comprise the Orthodontic and Implant Solutions segment.
公司預計將記錄非現金收入，涉及其兩個報告單位，即正畸矯正器解決方案和種植與修復解決方案，預期在$450 - $55000萬的範圍內出現商譽減值，稅後淨額，這兩個單位共同構成正畸和種植解決方案區間。
Several factors contributed to reductions to forecasted revenues, lower operating margins, and expectations for lower future cash flows in the near term, resulting in an impairment during the third quarter for the aforementioned reporting units.
多種因素導致了預測收入的減少，運營利潤率降低以及近期未來現金流預期較低，導致在第三季度上述報告單位出現減值。
譯文內容由第三人軟體翻譯。
